未登录

E

Eef L. Theunissen

Maastricht University

H指数:37

被引数:4,406

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cannabis perturbs dynamic brain states.

大麻扰乱动态脑状态。

Biological Psychiatry

IF9

2025-10-210

OAAI

Metabolomic profiling of cannabis use and cannabis intoxication in humans

NEUROPSYCHOPHARMACOLOGY

IF7.1

2025-03-010

OAAI

An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans

PSYCHOPHARMACOLOGY

IF3.3

2024-12-260

OAAI

Safety and cognitive pharmacodynamics following dose escalations with 3-methylmethcathinone (3-MMC): a first in human, designer drug study

NEUROPSYCHOPHARMACOLOGY

IF7.1

2024-12-240

OAAI

Inter-individual variability in neural response to low doses of LSD

TRANSLATIONAL PSYCHIATRY

IF6.2

2024-07-150

OAAI

A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

FRONTIERS IN PSYCHIATRY

IF3.2

2023-06-2026

OAAI

Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-06-1110

OAAI

Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review

Kratom (Mitragyna speciosa) 使用的临床意义: 文献综述

current pollution reports

IF4.6

2023-05-127

OAAI

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis

PSYCHOPHARMACOLOGY

IF3.3

2022-10-139

OAAI

A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence

FRONTIERS IN PSYCHIATRY

IF3.2

2022-05-194

OAAI

Cannabis Use and Neuroadaptation: A Call for Δ9-Tetrahydrocannabinol Challenge Studies

FRONTIERS IN PSYCHIATRY

IF3.2

2022-04-141

OAAI

Functional brain connectomes reflect acute and chronic cannabis use

SCIENTIFIC REPORTS

IF3.9

2022-02-1414

OAAI

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials

ADDICTION BIOLOGY

IF2.6

2021-12-2228

OA

Reply to: Managing the high: developing legislation and detection methods for cannabis impairment

NATURE REVIEWS NEUROSCIENCE

IF26.7

2021-07-201

OAAI

The why behind the high: determinants of neurocognition during acute cannabis exposure

NATURE REVIEWS NEUROSCIENCE

IF26.7

2021-05-2737

PREAI

State anxiety induced by THC and CBD does not change after correcting for baseline anxiety levels

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-03-010

PREAI

Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2021-03-0112

OAAI

Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis

PSYCHOPHARMACOLOGY

IF3.3

2021-01-2614

OAAI

Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2020-12-0175

OAAI

Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance A Randomized Clinical Trial

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IF55

2020-12-01103

OA